Allied Market Research
Loading...
0
Upcoming Allied Market Research
2021
Macular Degeneration Treatment Market

Macular Degeneration Treatment Market: Global Opportunity Analysis and Industry Forecast, 2020–2027

A11216
Pages: NA
Dec 2021 | 165 Views
   
Author(s) : Onkar Sumant
Tables: NA
Charts: NA
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Macular Degeneration Treatment Market

Request Now !

Macular Degeneration is one of the causes of vision loss. Macular Degeneration is triggered by the deterioration of the central portion of the retina, the inside back layer of the eye that records the images one sees and sends them via the optic nerve from the eye to the brain. The other part of the eye includes, the retina’s central portion, called as the macula, which is responsible for focusing central vision in the eye, and it controls our ability to drive a car, read, recognize faces or colors, and see objects in fine detail. There are three stages of AMD, which are Early AMD, wherein yellow deposits beneath retina is observed and can only be diagnosed during regular eye check-up. The second stage includes partial loss of the vision but sometimes noticeable symptoms may not be present. The last stage includes complete vision loss.

Market scope and structure analysis:

Report Metric

Details

  Market size available for years

  2020–2027

  Base year considered

  2019

  Forecast period

  2021–2027

  Forecast units

  Value (USD)

  Segments covered

  Type, Stage of Disease, Route of Administration, End User and Region

  Geographies covered

North America (U.S. and Canada), Europe (Germany, UK, France, and the Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), Latin America (Brazil, Mexico, and the Rest of LATAM) and The Middle East and Africa

  Companies covered

Major players analyzed include Novartis AG, F. Hoffmann-La Roche AG, Bausch Health Companies Inc., Regeneron, Ellex, REGENXBIO Inc., Aerie Pharmaceutical Inc., Panoptica, and Pfizer Inc.

 

COVID-19 scenario analysis:

Pharmaceutical and biotechnological companies have joined hands with governments around the globe to combat with the COVID-19 outbreak, for assisting in the development of various vaccines to ensure appropriate alternatives for medicines supply chain challenges. The estimates suggest that there are about 115 vaccine candidates and about 155 molecules, which are in the R&D pipeline. Due to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is hence anticipated to witness a significant growth for the newly developed drugs for the managements of the COVID-19 in the future. The current scenario has brought halt in the massive production of the medications used for macular degeneration treatment and also has broadly affected the supply of the medications, which is probing challenges for the major market players. However, the growing concern to lead healthy life has emerged due to the pandemic and hence, would propel the growth of this industry in the coming years.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

The major factors that are anticipated to affect the Macular Degeneration treatment market include the hike in the prevalence of retinal disorders and rise in the incidence of AMD in geriatric population would help the market grow in the coming years. Furthermore, the increase in R&D of the products, which can be used as a medication for AMD and surge in the approvals given by the government authorities for AMD treatment would help the market grow at a positive pace in the near future. However, the lack of awareness about the disease may hamper the growth of the industry during the forecast period.

The global Macular Degeneration Treatment market trends are as follows:

New product launches to flourish the market

The launch of new products for the treatment of macular degeneration is expected to help the growth of the market in the near future. For instance, in December 2019, Novartis announced that it would launch its new age-related macular degeneration drug in Europe after getting approval from the EMA’s main advisory committee. The Committee for Medicinal Products for Human Use (CHMP) issued a positive view for the drug Beovu (brolucizumab) as a treatment for neovascular or ‘wet’ AMD, a sight-robbing disease that affects the central part of the retina at the back of the eye.

Additionally, in July 2018, Allergan Plc., which is among the leading global pharmaceutical companies and Molecular Partners, which is a clinical-stage biopharmaceutical company, announced that they are developing a new class of drugs known as DARPin therapies. The companies also announced the release of two positive clinical trials, SEQUOIA, and CEDAR for abicipar, demonstrating that both the 8-week and 12-week treatment regimens met the pre-specified primary endpoint of non-inferiority to ranibizumab. SEQUOIA and CEDAR are identical global phase-3 studies designed to assess the efficacy and safety of abicipar compared with ranibizumab in treatment-naive patients with neovascular age-related macular degeneration (AMD).

Surge in incidences of AMD to boost the market

The growth in the number of individuals who are susceptible to have Macular Degeneration is expected to help the market gain maximum shares in the coming years. According to the statistics given by the Bright Focus Foundation, about 11 million people in the U.S. have some form of age-related macular degeneration. Additionally, the number is expected to double to nearly 22 million by 2050 according to the growth rate.

Furthermore, the total number of people living with macular degeneration is anticipated to reach 196 million worldwide by 2020 and rise to about 288 million by 2040. The foundation also stated that age is a prominent risk factor for age-related macular degeneration. The risk of getting advanced age-related macular degeneration upsurges from 2% for those ages 50-59, to approximately 30% for those over the age of 75.

Key segments covered:

Segments

Sub-segments

  Type

  • Dry Age related macular degeneration
  • Wet Age-related macular degeneration

  Stage of Disease

  • Early Stage AMD
  • Intermediate Stage AMD
  • Late Stage AMD

  Route of Administration

  • Intravenous
  • Intravitreal

  End User

  • Hospitals and Clinics
  • Ambulatory Surgical Center
  • Others


Key benefits of the report:

  • This study presents the analytical depiction of the global macular degeneration treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global macular degeneration treatment market share.
  • The current market is quantitatively analyzed from 2020 to 2027 to highlight the global Macular Degeneration Treatment market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the macular degeneration treatment market.
  • The report provides a detailed global macular degeneration treatment market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the macular degeneration treatment market research report:

  • Which are the leading market players active in the macular degeneration treatment market?
  • What current trends will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities in the macular degeneration treatment market?
  • What are the projections for the future that would help in tasking further strategic steps?
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
PURCHASE OPTIONS

Start reading ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
Allied Market Research Allied Market Research Allied Market Research

Access from any device, anywhere

Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

FREQUENTLY ASKED
QUESTIONS?

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

REQUEST TOC/SAMPLE

OR

Purchase Full Report of
Macular Degeneration Treatment Market

Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456  $3,110
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840  $3,456
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,769  $5,192
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450  $5,805
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,995  $8,996
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers